• Latest Posts

BioGeneration Ventures closes BGV Fund V at €150M 

Expert Advice 2 Mar 2023

5 steps to strategic partnerships for healthtech startups

Lyvgen and Bristol Myers Squibb commitment to transform cancer care

A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation

New research boosts Nordic Bioscience’s PRO-C6 as biomarker assay for trial enrichment in HFpEF

Treatment for adults with moderate to severe psoriasis approved by FDA


Amphista Lands Megadeals to Smash Cancer using Protein Degradation

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

In Depth 9 Apr 2018

Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?

Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?

Will BMS Take Over a Danish Biotech in a Massive €400M Deal?

French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial